Researchers have identified a promising drug candidate, DDL-357, that improves memory in Alzheimer’s mouse models by increasing levels of a protective brain protein called clusterin (CLU). CLU helps prevent the buildup of toxic amyloid-beta plaques and tau proteins, both key drivers of Alzheimer’s disease.
